

Supplementary Table 1: Associations between selected fastidious bacterial vaginosis associated bacteria<sup>a</sup>, ureaplasma bacteria, and histologically confirmed endometritis<sup>b</sup> in a subset of women without gonorrhea and chlamydia at baseline

	Endometritis + n=115 n/N (%)	Endometritis - n=232 n/N (%)	Adjusted OR <sup>γ</sup> (95% CI)
<b>BV-associated bacteria<sup>a</sup> (1 or more +)</b>			
Cervix and/or endometrium	94/115 (81.7)	198/232 (85.3)	0.7 (0.4 – 1.3)
Endometrium	67/113 (59.3)	128/229 (55.9)	1.1 (0.7 – 1.7)
<b>BV-associated bacteria<sup>a</sup> (all +)</b>			
Cervix and/or endometrium	30/51 (58.8)	60/94 (63.8)	0.7 (0.3 – 1.5)
Endometrium	7/53 (13.2)	12/113 (10.6)	1.1 (0.4 – 3.1)
<b><i>Ureaplasma urealyticum</i></b>			
Cervix and/or endometrium	41/110 (37.3)	49/218 (22.5)	2.2 (1.3 – 3.7)
Endometrium	13/113 (11.5)	17/229 (7.4)	1.8 (0.8 – 3.8)
<b><i>Ureaplasma parvum</i></b>			
Cervix and/or endometrium	56/110 (50.9)	130/219 (59.4)	0.7 (0.5 – 1.2)
Endometrium	22/113 (19.5)	41/229 (17.9)	1.2 (0.6 – 2.1)

<sup>a</sup> *Leptotrichia sanguinegens*, *Leptotrichia amnionii*, *Atopobium vaginae*, and BVAB1. Comparison group consists of women who tested negative for all four bacteria. In model of “all positive”, women testing positive for some but not all bacteria are excluded.

<sup>b</sup>  $\geq 5$  surface epithelium neutrophils per  $\times 400$  field absent of menstrual endometrium and/or  $\geq 2$  stromal plasma cells per  $\times 120$  field

<sup>γ</sup> Adjusted for age and race

Supplementary Table 2: Associations between selected fastidious bacterial vaginosis-associated bacteria <sup>α</sup>, ureaplasma bacteria, and histologically confirmed endometritis <sup>β</sup> 30 days following treatment for pelvic inflammatory disease in a subset of women without gonorrhea and chlamydia at 30 days

	Endometritis <sup>β</sup> + n=117 n/N (%)	Endometritis <sup>β</sup> - n=175 n/N (%)	Adjusted RR <sup>γ</sup> (95% CI)
<b>BV-associated bacteria (1 or more +) <sup>α</sup></b>			
Cervix and/or endometrium	102/117 (87.2)	149/175 (85.1)	1.1 (0.5 – 2.5)
Endometrium	75/114 (65.8)	114/174 (65.5)	1.0 (0.6 – 1.8)
<b>BV-associated bacteria (all positive) <sup>α</sup></b>			
Cervix and/or endometrium	29/44 (65.9)	27/53 (50.9)	2.8 (1.0 – 7.8)
Endometrium	10/49 (20.4)	4/64 (6.3)	8.5 (1.6 – 44.6)
<b><i>Ureaplasma urealyticum</i></b>			
Cervix and/or endometrium	28/113 (24.8)	39/172 (22.7)	1.2 (0.6 – 2.3)
Endometrium	7/115 (6.1)	8/174 (4.6)	1.4 (0.4 – 4.8)
<b><i>Ureaplasma parvum</i></b>			
Cervix and/or endometrium	48/115 (41.7)	49/173 (28.3)	1.9 (1.1 – 3.5)
Endometrium	18/115 (15.7)	19/174 (10.9)	2.7 (1.2 – 6.2)

<sup>α</sup> *Leptotrichia sanguinegens*, *Leptotrichia amnionii*, *Atopobium vaginae*, and BVAB1

<sup>β</sup> ≥5 surface epithelium neutrophils per ×400 field absent of menstrual endometrium and/or ≥2 stromal plasma cells per ×120 field

<sup>γ</sup> Adjusted for age, race, and self-reported partner treatment

Supplementary Table 3: Long-term sequelae following PID with selected fastidious bacterial vaginosis-associated<sup>a</sup> and ureaplasma bacteria in a subset of women without gonorrhea and chlamydia at baseline

	Cervical and/or Endometrial BV-associated bacteria: 1 or more + N=334 n (%)	Cervical and/or Endometrial BV-associated bacteria: All negative N=55 n (%)	Adjusted RR <sup>β</sup> (95% CI)	Endometrial BV-associated bacteria: 1 or more + N=225 n (%)	Endometrial BV-associated bacteria: All negative N=156 n (%)	Adjusted RR <sup>β</sup> (95% CI)
Recurrent PID	72 (22.9)	8 (15.1)	1.4 (0.6 – 3.2)	56 (26.0)	23 (15.9)	1.6 (0.9 – 2.9)
Infertility	70 (21.3)	5 (9.1)	2.6 (1.0 – 6.8)	51 (23.1)	25 (16.2)	1.5 (0.9 – 2.6)
Chronic Pelvic Pain	153 (47.4)	26 (49.1)	1.0 (0.6 – 1.8)	96 (44.0)	78 (51.7)	0.8 (0.5 – 1.2)
	Cervical and/or Endometrial BV-associated bacteria: All positive N=107 n (%)	Cervical and/or Endometrial BV-associated bacteria: All negative N=55 n (%)	Adjusted RR <sup>α</sup> (95% CI)	Endometrial BV-associated bacteria: All positive N=25 n (%)	Endometrial BV-associated bacteria: All negative N=156 n (%)	Adjusted RR <sup>β</sup> (95% CI)
Recurrent PID	29 (29.0)	8 (15.1)	1.9 (0.8 – 4.9)	11 (47.8)	23 (15.9)	4.7 (1.7 – 12.8)
Infertility	26 (25.0)	5 (9.1)	3.4 (1.1 – 10.4)	3 (12.0)	25 (16.2)	0.7 (0.2 – 2.8)
Chronic Pelvic Pain	42 (40.8)	26 (49.1)	0.8 (0.4 – 1.5)	13 (52.0)	78 (51.7)	1.1 (0.5 – 2.8)
	Cervical and/or Endometrial UU + N=102 n (%)	Cervical and/or Endometrial UU – N=263 n (%)	Adjusted RR <sup>α</sup> (95% CI)	Endometrial UU + N=36 n (%)	Endometrial UU – N=344 n (%)	Adjusted RR <sup>β</sup> (95% CI)
Recurrent PID	24 (25.5)	52 (20.7)	1.3 (0.7 – 2.3)	10 (30.3)	69 (21.1)	1.8 (0.8 – 4.0)
Infertility	19 (19.0)	52 (20.0)	1.0 (0.5 – 1.8)	7 (20.0)	69 (20.3)	1.0 (0.4 – 2.4)
Chronic Pelvic Pain	54 (54.5)	115 (44.9)	1.5 (1.0 – 2.5)	21 (60.0)	153 (45.8)	1.9 (0.9 – 3.8)
	Cervical and/or Endometrial UP + N=213 n (%)	Cervical and/or Endometrial UP – N=157 n (%)	Adjusted RR <sup>α</sup> (95% CI)	Endometrial UP + N=72 n (%)	Endometrial UP – N=308 n (%)	Adjusted RR <sup>β</sup> (95% CI)
Recurrent PID	44 (21.5)	32 (22.2)	1.0 (0.6 – 1.7)	18 (25.7)	61 (21.0)	1.3 (0.7 – 2.5)
Infertility	43 (20.3)	28 (18.3)	1.1 (0.6 – 1.8)	13 (18.1)	63 (20.8)	0.9 (0.5 – 1.8)
Chronic Pelvic Pain	94 (45.4)	78 (51.3)	0.8 (0.5 – 1.2)	36 (50.7)	138 (46.3)	1.2 (0.7 – 2.1)

<sup>a</sup>*Leptotrichia sanguinegens*, *Leptotrichia amnionii*, *Atopobium vaginae*, and BVAB1. Comparison group consists of women who tested negative for all four bacteria. In model of “all positive”, women testing positive for some but not all bacteria are excluded.

<sup>β</sup> All models are adjusted for age and race. Infertility model additionally adjusted for self-reported infertility at baseline.